安科生物(300009.SZ)擬4000萬元增資阿法納全資子公司 推動“新冠奧密克戎等突變株mRNA疫苗”項目研發及產業化
格隆匯5月16日丨安科生物(300009.SZ)公吿稱,公司(“乙方”)於2022年4月12日與合肥阿法納生物科技有限公司(簡稱“阿法納”或“甲方”)簽署了《戰略合作框架協議》,雙方建立戰略合作伙伴關係,充分發揮各自優勢,就“新冠奧密克戎等突變株mRNA疫苗”的臨牀前研究、臨牀研究、產業化及市場銷售工作等方面開展排他性合作。
基於上述《戰略合作框架協議》,公司與阿法納於近日簽署了正式《合作協議》,就合作開展“新冠奧密克戎等突變株mRNA疫苗”的研發與產業化達成共識。合作事項包括:
1、本着進一步明確雙方權利義務、有利於保障公司作為出資方及產業化支持方的利益、有利於維護上市公司及全體股東權益的原則,經雙方友好協商,本次通過乙方增資甲方新設全資子公司合肥阿法納安科生物科技有限公司(暫定名,以工商部門最終核准名稱為準)(簡稱“阿法納安科”)來實現本項目研發及產業化,並由阿法納安科承擔本項目的費用支出。
乙方以自有資金人民幣4,000萬元對阿法納安科增資,按照本協議約定的里程碑,分階段向阿法納安科支付增資款,用於開展本項目臨牀試驗等相關研發工作。全部增資完成後,乙方持有阿法納安科40%股權。
2、乙方同意通過自有基金或直投等方式參與甲方的A輪融資,投資協議另行簽訂。
3、乙方承諾,未經甲方書面文件許可,乙方自身及其相關聯的公司、組織、機構自本協議簽署後十年內,不得開展與mRNA技術平台有關的任何藥物和應用技術的開發工作。
4、甲方承諾,在阿法納安科存續期間,不會就“新冠奧密克戎等突變株mRNA疫苗”項目與任何其他第三方以任何形式開展商業合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.